Zhi Tong Cai Jing·2025-06-21 03:09Core Insights - Major pharmaceutical companies Eli Lilly (LLY.US), Novo Nordisk (NVO.US), and Amgen (AMGN.US) are set to present significant clinical trial results at the 85th American Diabetes Association (ADA) Scientific Sessions from June 20 to 23 [1][2] Group 1: Eli Lilly - Eli Lilly will present the results of its Phase 3 clinical trial for the oral weight loss therapy orforglipron on June 21, which showed an average weight loss of approximately 8% over a 40-week period [1] - The company previously announced the final data from the ACHIEVE-1 trial, which was the first of seven Phase 3 trials for orforglipron [1] Group 2: Novo Nordisk - Novo Nordisk will present data from its next-generation weight loss therapy CagriSema's REDEFINE1 and REDEFINE2 Phase 3 clinical trials on June 22 [2] - The company's stock experienced a significant decline in December due to the REDEFINE1 trial not meeting initial expectations, targeting adults with obesity or overweight and related conditions [1][2] Group 3: Amgen - Amgen will focus on the safety of its experimental weight loss therapy MariTide, with full data from a Phase 2 clinical trial to be released on June 23 [2] - The trial reported an average weight loss of up to 20% over 52 weeks for participants with obesity or overweight but without type 2 diabetes, leading to a decline in Amgen's stock in November [2] - A report from Cantor Fitzgerald highlighted potential safety concerns regarding bone mineral density decline associated with MariTide [2] Group 4: Other Companies - Other notable companies presenting at the ADA conference include Altimmune (ALT.US), Metsera (MTSR.US), and Vertex Pharmaceuticals (VRTX.US) [2]